GB2459910A — Sustained release corticosteroid compositions for treatment of otic disorders
Assigned to Otonomy Inc · Expires 2009-11-11 · 17y expired
What this patent protects
A pharmaceutical composition for the treatment of otic disorders, such as Meniere's disease or sudden sensineural hearing loss, is disclosed, wherein the sustained release of the corticosteroids dexamethasone, methylprednisolone or prednisolone is provided into the cochlea for at…
USPTO Abstract
A pharmaceutical composition for the treatment of otic disorders, such as Meniere's disease or sudden sensineural hearing loss, is disclosed, wherein the sustained release of the corticosteroids dexamethasone, methylprednisolone or prednisolone is provided into the cochlea for at least 14 days. The composition comprises a corticosteroid and between 16-21% by weight polyoxyethylene-polyoxypropylene triblock copolymer of the formula E106 P70 E106, and water buffered to a perlymph-suitable pH, and has a perilymph suitable osmolarity of between 250-320mMm and contains less than 50 colony forming unit microbial agents per gram of formulation. The formulation is preferably in the form of an auris-acceptable thermoreversible gel, and the sustained release matrix preferably comprises Pluronic F-127 RTM (poloxamer 407).
Drugs covered by this patent
- Cipro (Ciprofloxacin) · Alk Abello
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.